Facebook
Linkedin
Twitter
Home
Phil’s Posts
MEMBERS ONLY
Top Trades
Virtual Portfolio Review
Webinars
BNN Money Talk
Market Charts
AI
Biotech
Perspectives
Politics
Science
Strategy
Tech
Trading Education
Contact Us
An invitation from Phil
SIGN IN
SUBSCRIBE
Privacy Policy
Search
Sign in
Welcome! Log into your account
your username
your password
Log in With Facebook
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
10.2
C
New York
Saturday, February 28, 2026
Sign In
Home
Phil’s Posts
MEMBERS ONLY
Top Trades
Virtual Portfolio Review
Webinars
BNN Money Talk
Market Charts
AI
Biotech
Perspectives
Politics
Science
Strategy
Tech
Trading Education
Contact Us
An invitation from Phil
SIGN IN
SUBSCRIBE
Privacy Policy
Home
Tags
GlaxoSmithKline
Tag:
GlaxoSmithKline
Perspectives
U.K. Medical Journal Questions Avandia License
Ilene
-
September 6, 2010
Perspectives
After Avandia: Does the FDA Have a Drug Problem?
Ilene
-
August 14, 2010
Hot Items
Something to Love about GSK
Ilene
-
June 23, 2010
Perspectives
Study Suggests HPV Vaccine Is Safe, but Doctors Wary
Ilene
-
August 19, 2009
Stay Connected
0
Fans
Like
3,912
Followers
Follow
22,800
Subscribers
Subscribe
Latest Articles
AI
Anthropic CEO responds to Trump order, Pentagon clash
Markets
☢️ World War Trump: The Pentagon Ultimatum – AI Weaponization and Constitutional Collapse
Markets
Zeihan: Attack on Iran Underway
Charts
PSW’s Weekly Webinar: The State of the Markets Report (2/25/2026)
Markets
Trump Orders Government to Stop Using Anthropic After Pentagon Standoff
Markets
Fall Back Friday – February Ending on a Week Note?
Markets
AI “hot takes” are becoming a market risk
Markets
How Trump’s renewed tariff chaos will stifle investment around the world
Market News
Netflix Backs Out of Bid for Warner Bros., Paving Way for an Ellison Takeover
AI
Anthropic Takes a Stand
Markets
A Modest Proposal For Solving the AI Energy Crisis
Markets
Thursday Thrust: One Stock to Rule Us All (NVDA, of course!)
Load more